NAGE

Niagen Bioscience Inc
$2.72
+0.03 (+1.12%)
Mkt Cap 216.63M
Volume 361,056
52W Range 2.61-7.95
Sector Healthcare
Beta 2.02
EPS (TTM) 0.19 USD
P/E Ratio 14.01
Revenue (TTM) 129.08M USD
Rev Growth (5Y) +16.9%
EPS Growth (5Y) N/A
AlphaVal · Fair Value
What we estimate one share is worth
$5.20
Undervalued strong signal
47.7% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 129.42M 99.60M 83.57M 72.05M 67.45M 59.26M 46.29M 31.56M 21.20M 21.66M 17.88M 15.31M
Net Income 17.38M 8.55M (4.94M) (16.54M) (27.13M) (19.93M) (32.15M) (33.32M) (11.38M) (2.93M) (2.77M) (5.39M)
EPS 0.22 0.11 -0.07 -0.24 -0.40 -0.33 -0.56 -0.61 -0.26 -0.08 -0.08 -0.15
Free Cash Flow 13.14M 11.95M 6.97M (15.43M) (24.57M) (10.74M) (21.19M) (22.36M) (11.15M) (4.66M) (2.76M) (2.83M)
FCF / Share 0.17 0.15 0.10 -0.22 -0.37 -0.18 -0.37 -0.41 -0.25 -0.12 -0.08 -0.08
Operating CF 13.44M 12.11M 7.12M (15.10M) (24.16M) (10.60M) (20.44M) (20.91M) (9.80M) (2.94M) (2.11M) (2.58M)
Total Assets 106.41M 68.28M 54.96M 54.06M 57.84M 38.36M 40.25M 42.23M 62.72M 19.75M 18.75M 11.52M
Total Debt 2.82M 2.65M 3.28M 4.26M 4.70M 1.64M 1.72M 310,000 506,000 599,050 5.54M 2.77M
Cash & Equiv 64.79M 44.51M 27.17M 20.29M 28.02M 16.50M 18.61M 22.42M 45.39M 1.64M 5.55M 3.96M
Book Value 76.53M 46.09M 28.46M 28.67M 31.73M 16.42M 20.45M 27.18M 53.83M 9.97M 5.27M 4.00M
Return on Equity 0.23 0.19 -0.17 -0.58 -0.86 -1.21 -1.57 -1.23 -0.21 -0.29 -0.53 -1.35
NAGE News
Niagen Bioscience to Present at LD Micro 20th Annual Main Event
Oct 06, 2026 04:32 AM · businesswire.com
Niagen Bioscience Puts 25 Years of NAD+ Science Behind "Don't Get Old. Age Better.
Oct 01, 2026 04:32 AM · businesswire.com
Niagen Bioscience Announces Start-Up Agreement With Mass General Brigham (MGB) Investigators For First-Of-Its-Kind Healthy Aging Clinical Trial
Sep 30, 2026 04:32 AM · businesswire.com
Niagen Bioscience, Inc. (NASDAQ:NAGE) Given Average Recommendation of “Buy” by Analysts
Sep 23, 2026 10:15 PM · defenseworld.net
Newly Published Preclinical Study Demonstrates CD38 as a Driver of Age-Related NAD+ Decline, Older Mothers Have Lower NAD+ Levels in Placental Tissue, and NAD+ Restoration with Nicotinamide Riboside (NR) Improves Pregnancy Outcomes
Sep 21, 2026 04:32 AM · businesswire.com
Niagen Bioscience Engages Veteran Pharmaceutical Executives and Biotechnology Experts to Support Drug Development Program and Strategic Business Growth
Sep 17, 2026 04:32 AM · businesswire.com
Niagen Bioscience to Present at Canaccord Genuity's Well Summit
Sep 10, 2026 04:32 AM · businesswire.com
Niagen Bioscience to Present at Longevity Investors Conference
Sep 02, 2026 04:32 AM · businesswire.com
Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
Aug 26, 2026 05:00 AM · gurufocus.com
Niagen Bioscience to Present at Nasdaq X LD Micro Inaugural SF Summit
Aug 26, 2026 04:32 AM · businesswire.com